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Abstract: The development of multiple agents with potent antiretroviral activity against HIV 
has ushered in a new age of optimism in the management of patients infected with the virus. 
However, the viruses’ dynamic ability to develop resistance against these agents necessitates the 
investigation of novel targets for viral suppression. Raltegravir represents a first-in-class agent 
targeting the HIV integrase enzyme, which is responsible for integration of virally encoded DNA 
into the host genome. Over the last 5 years, clinical trials data has demonstrated an   increasing 
role for raltegravir in the management of both treatment-experienced and treatment-naïve 
HIV-1-infected patients. This review focuses on the evidence supporting raltegravir’s efficacy 
in an array of clinical settings. Other HIV-1 integrase inhibitors in development are also briefly 
discussed.
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Introduction
According to the World Health Organization (WHO), 33 million people are currently 
living with HIV worldwide.1 Fortunately 30 years into the epidemic, an entire arsenal 
of medications is available to combat the replication of the virus in resource-rich parts 
of the world. Most of these antiretrovirals have targeted inhibition of two enzymes 
critical for viral replication: protease and reverse transcriptase. More recently devel-
oped drugs are capable of inhibiting viral fusion with host cells (enfurvitide) and 
viral entry via the chemokine co-receptor-5 (CCR-5) site (maraviroc) on CD4+ cells. 
Raltegravir (Isentress®, Merck) represents a first-in-class antiretroviral that targets the 
integrase enzyme, which is primarily responsible for integrating virally encoded DNA 
into the host genome.2 In the 4 years since the approval of raltegravir by the US Food 
and Drug Administration (FDA), it has assumed an increasing role in the treatment 
of antiretroviral-naïve patients, while remaining a cornerstone of salvage regimens in 
treatment-experienced patients.
HIV integration
The integration of HIV-1-derived DNA into the host genome is a two-step process 
separated chronologically and geographically, mediated by the HIV-1 integrase (IN) 
enzyme. After the transcription of the viral DNA by reverse transcriptase in the 
  cytoplasm, the integrase enzyme binds the DNA in a specific region of long-term 
repeats. The first step of integration involves the cleavage of 2 nucleotides at the 3′ 
end of the viral DNA leaving suitable 3′-OH ends for integration of the DNA into the 
host genome. The IN enzyme remains bound to the DNA after cleavage and, along HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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with a number of other bound viral proteins, forms the 
  preintegration complex (PIC). The PIC then migrates into 
the host nucleus for the second part of integration, strand 
transfer. Finally, host DNA is cleaved by the IN enzyme, and 
the 3′-OH ends are ligated to the host DNA3–8 (Figure 1).
Integrase inhibitors all appear to block integration via a 
similar mechanism. The target is the catalytic binding site of 
divalent cations to the IN enzyme in the catalytic core domain 
(CCD). Specifically, integrase inhibitors chelate Mg2+ from 
the DDE motif in the CCD rendering the enzyme unable to 
complete strand transfer.9 Although reports of compounds 
that inhibit HIV-1 integrase date back almost 20 years, the 
major breakthrough in the development of clinically effec-
tive integrase inhibitors was the identification of diketo 
acid derivatives as selective inhibitors of the strand transfer 
reaction mediated by the IN enzyme in 2000.6 A seminal 
report by Hazuda et al demonstrated that these compounds 
were able to inhibit HIV-1 without affecting reverse tran-
scriptase activity, solely by inhibition of strand transfer by 
the IN enzyme.10 Diketo acid moieties have the ability to 
chelate magnesium from the active site of the IN enzyme 
thus   rendering the metal-dependent phosphotransferase 
responsible for strand transfer inactive.9,11 Continued research 
revealed that the naphthyridine carboxamide derivatives are 
also capable of activity against HIV integrase indistinguish-
able from the diketo acids. A compound with a naphthyridine 
carboxamides moiety was the first to suppress simian-human 
immunodeficiency virus (SHIV) successfully in rhesus 
  macacques via the virus’ integrase.12 Raltegravir (MK-0518), 
is a direct result of the optimization of compounds related to 
the   naphthyridine carboxamide family.13
Pharmacology and drug 
interactions
Raltegravir has potent activity against HIV-1 with a 95% 
inhibitory concentration (IC95) of 31 nmol/L in human T 
lymphoid cell cultures incubated in 50% human serum. It also 
has activity against HIV-2 in vitro.2 Raltegravir’s antiviral 
activity is synergistic when incubated with other nucleoside 
reverse transcriptase inhibitors (NRTIs) and non-nucleoside 
reverse transcriptase inhibitors (NNRTIs) in vitro. Usual 
dosage for raltegravir is 400 mg twice daily with or without 
food.2 Single dose studies in HIV-uninfected persons revealed 
a biphasic peak in drug concentrations, with an initial peak 
at 1 hour. The terminal half-life was approximately 9 hours 
with steady state usually achieved after approximately 
2 days. Raltegravir is absorbed quite rapidly with a median 
time to maximum concentration (Tmax) of approximately 
3 hours, although this is highly variable among individu-
als. The drug is eliminated mostly by hepatic metabolism 
via the uridine diphosphate glucuronosyltranferase 1A1 
(UGT1A1)   pathway. UGT1A1 converts raltegravir to its 
primary metabolite through the process of glucuronidation. 
Oral bioavailability is approximately 30%.14
Food intake has no clinically significant impact on ralte-
gravir’s absorption. Age or gender does not appear to play a 
role in the drug’s pharmacokinetics either.2 Data on pharma-
cokinetics for extremely underweight (BMI , 18) or over-
weight (BMI . 37) individuals are not available. Findings 
from a single dose study evaluating the effect of   moderate 
hepatic insufficiency on raltegravir metabolism showed 
that although the C12h was higher in subjects with moderate 
hepatic impairment (C12h ratio 1.26, 90% CI 0.41–1.77), 
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Figure 1 Schematic representation of HIV integration and the mechanism of raltegravir.
Note: *Cellular functions.
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the difference did not reach statistical significance.15 There 
was also no significant difference in the mean area under 
the curve (AUC) between the two groups of subjects. Only 
9% of raltegravir is excreted unchanged through the urine. 
Accordingly, there was no statistically significant difference 
between the AUC, Cmax, or C12h of subjects with severe renal 
impairment (GFR , 30 mL/min) and those with normal renal 
function.15 Minimal clearance of raltegravir by hemodialysis 
is suggested in a few case reports.16,17 Raltegravir appears to 
be well distributed in the body, reaching concentrations that 
exceed the IC95 in cerebrospinal fluid (CSF), seminal and 
cervicovaginal fluid.14,18
Raltegravir has a low propensity for drug–drug interac-
tions. In vitro studies with human hepatocyte cultures have 
shown that it does not inhibit or induce any of the major 
cytochrome P450 enzymes. It is a substrate, but not an 
inhibitor of p-glycoprotein. Raltegravir has no significant 
effect on the pharmacokinetics of methadone, lamotrigine, 
midazolam, or proton pump inhibitors.14,19 An important 
exception to this favorable drug interaction profile of ralte-
gravir is rifampin, an important antituberculosis drug and 
a potent inducer of UGT1A1. Multiple studies have shown 
that rifampin   significantly decreases the C12h, AUC, and Cmax 
of raltegravir in vivo. Thus, the FDA recommended dose of 
raltegravir when used with rifampin is 800 mg twice daily.2 
However, rifabutin is the preferred rifamycin for the treatment 
of tuberculosis in patients taking raltegravir.20
Raltegravir and other antiretrovirals do not affect 
the pharmacokinetics of one another in most instances 
(Table 1). However, 3 studies show that raltegravir plasma 
levels are significantly increased when it is administered 
with atazanavir. The aggregate C12h, AUC, and Cmax ratios 
(raltegravir + atazanavir/raltegravir) were 1.95 (90% CI 
1.30–2.92), 1.72 (90% CI 1.47–2.02), and 1.53 (90% CI 
1.11–2.22), respectively.14,21 Conversely, raltegravir has been 
shown to modestly decrease the levels of atazanavir in HIV-
uninfected individuals.14 Given differences in the gastric pH 
of HIV-infected persons, plasma concentrations are expected 
to be even lower in these patients. Of note, the above phar-
macokinetic studies on atazanavir were conducted without 
ritonavir boosting. In a recent clinical trial, there was a high 
incidence of hyperbilirubinemia in patients taking the two 
medications concurrently.22 Tenofovir modestly increases 
plasma concentrations of raltegravir in HIV-uninfected 
Table 1 Summary of raltegravir interactions with selected antiretrovirals and adverse reactions with co-administration (if any)
Antiretroviral agent Effect on RAL levels RAL effect on ARV levels Adverse effects of  
RAL + ARV
Reference
Protease inhibitors
Atazanavir ↑Cmin 95%, AUC 72%, ↑Cmin 29%, AUC 17%, n/a 21
Cmax 53% Cmax 11%
Atazanavir/r ↑Cmin 77%, AUC 41%, n/a Hyperbilirubinemia 21,22
Cmax 24%
Fosamprenavir ↓Cmin 38%, AUC 37%, ↓Cmin 43%, AUC 36%, None reported 14
Cmax 28% Cmax 27%
Lopinavir/r ↓Cmin 30%, ↑AUC 3%, ↑Cmin 4%, ↓AUC 1%, None reported 14
Cmax 64% ↓Cmax 3%
Tipranavir/r ↓Cmin 55%, AUC 24%, n/a None reported 78
Cmax 18%
Darunavir/r ↑Cmin 38%, ↓AUC 29% ↓Cmin 39% Rash 79
↓Cmax 33%
NRTI/NNRTI
Abacavir n/a ↓Cmin 17%,↑AUC 3%, None reported 14
↓Cmax 6%
Tenofovir ↑Cmin 3%, AUC 49%, ↓Cmin 13%, AUC 10% None reported 23
Cmax 64% Cmax 23%
etravirine ↓Cmin 34%, AUC 10%, ↑Cmin 17%, AUC 10% None reported 80
Cmax 11% Cmax 4%
efavirenz ↓Cmin 21%, AUC 36%, n/a None reported 24
Cmax 36%
CCR-5 inhibitors
Maraviroc ↓Cmin 28%, AUC 37%, ↓Cmin 10%, AUC 14% None reported 14
Cmax 33% Cmax 20%
Abbreviations: ARV, antiretroviral agents; AUC, area under the concentration-time curve; Cmin, minimum concentration; Cmax, maximum concentration; CCR-5, chemokine 
co-receptor 5; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; RAL, raltegravir.HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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individuals, but in HIV-1 infected individuals, the effect 
is attenuated. Conversely, raltegravir modestly decreases 
tenofovir plasma levels. None of these findings appear to be 
clinically significant.23 Ritonavir also does not appear to affect 
the pharmacokinetics of raltegravir.24 Raltegravir AUCs in 
coadministration studies with efavirenz, fosamprenavir, and 
maraviroc showed decreases of 36%, 37%, and 36% respec-
tively compared with control subjects.14,24,25 One recent study 
also showed that the AUC of darunavir was decreased by up 
to 44% when co-administered with raltegravir.26 In all these 
studies, changes in the antiviral activity of both medications 
were not clinically significant. Dose adjustment of raltegravir 
with these antivirals is not warranted.
Clinical trials
Treatment-naïve patients
The first published data demonstrating efficacy of ralte-
gravir in antiretroviral-naïve HIV-1 infected humans was 
the first portion of the Protocol 004 study. Four groups of 
6 to 8 patients were assigned to receive 100 mg, 200 mg, 
400 mg, or 600 mg of raltegravir twice daily for 10 days as 
monotherapy vs placebo (n = 7). The aim of the study was 
to quantify the anti-retroviral activity of raltegravir, but 
also to assess its safety and tolerability in the short term. 
On day 10, the mean decrease in HIV-1 RNA was 1.9log10 
copies/mL in the 100 mg group, 2.0log10 copies/mL in the 
200 mg group, 1.7log10 copies/mL in the 400 mg group, and 
2.2log10 copies/mL in the 600 mg group. The mean decrease 
in the placebo group was 0.2log10 copies/mL (P ≤ 0.001 vs 
raltegravir). Impressively, about 50% of the subjects in the 
study had achieved an HIV-1 RNA level of ,400 copies/mL 
in the 10-day study period. The clinical significance of such a 
rapid decline in HIV-1 RNA in the serum is still unclear.27
Given the above results, Protocol 004 was expanded 
to include more treatment-naïve patients over an intended 
96-week study period; 160 treatment-naïve patients (includ-
ing the 26 patients from Part I) were divided into 4 groups to 
take 100 mg, 200 mg, 400 mg or 600 mg of raltegravir twice 
daily with an NRTI backbone of lamivudine and tenofovir. 
The control group was 38 patients (4 from Part I) who took 
600 mg of efavirenz once daily with the same NRTI back-
bone. Key patient characteristics for the 198 patients treated 
include a mean baseline CD4 count of 300 cells/mm3 and a 
baseline viral load of 4.6 to 4.8log10 HIV RNA copies/mL. 
The primary endpoint was the proportion in each group with 
HIV-1 RNA , 400 copies/mL with a secondary endpoint of 
HIV-1 RNA of ,50 copies/mL, now the widely accepted 
standard for viral suppression. At 48 weeks, 85% of patients 
in the 100 mg twice daily group, 83% in the 200 mg group, 
88% in 400 mg group, and 88% in the 600 mg group achieved 
HIV-1 RNA levels of ,50 copies/mL. In the efavirenz group, 
87% attained the same level of suppression. After 48 weeks, 
all raltegravir patients were switched to the subsequently 
FDA-approved dose of 400 mg twice daily.28 Data from 96 
weeks confirmed sustained viral suppression with 83% in the 
raltegravir group maintaining HIV RNA , 50 copies/mL vs 
84% in the efavirenz group (Table 2). CD4 count increases 
were also similar in both groups over the study period 
(221 cells/uL in raltegravir group vs 232 cells/uL in efa-
virenz group). Adverse event profiles were similar in both 
groups.29
Given the success of the Phase II studies, a multicenter, 
randomized, double-blind trial (STARTMRK) was initiated 
to establish noninferiority of a raltegravir-based regimen vs 
the established treatment standard efavirenz-based regimen. 
A total of 563 patients was randomized to receive either 
  raltegravir 400 mg twice daily or efavirenz 600 mg once 
daily. Both groups also received a fixed dose combination 
emtricitabine/tenofovir NRTI backbone as part of the regimen. 
Key patient characteristics included a mean baseline viral load 
of 5.0log10 HIV RNA copies/mL, with 53% of the patients 
having a baseline viral load . 100,000 copies per/mL. The 
mean age of the study population was 37.3 years. Of the study 
participants, 18% were women and 42% were white; 48% had 
a CD4 count of ,200 cells/uL. The primary endpoint was 
viral suppression , 50 copies/mL HIV RNA. After 48 weeks, 
86.1% of the raltegravir group achieved the primary endpoint 
compared with 81.9% of the efavirenz group. As in prior trials, 
time to viral suppression was much shorter in the raltegravir 
group.30 Of patients from the initial trial period, 84% remained 
in the study for 96-weeks follow up. In the intention-to-treat 
analysis, all noncompleters were treated as failures. At 96 
weeks, 81% of the patients in the raltegravir group and 79% of 
the patients in the efavirenz group maintained HIV RNA levels 
of ,50 copies/uL. Although there was a significantly higher 
increase in CD4 count in the raltegravir group at 48 weeks, 
the difference between the groups did not meet statistical 
significance at 96 weeks (240 cells/µL vs 225 cells/µL in the 
raltegravir and efavirenz groups respectively, ∆ 15 cells, 95% 
CI -13 to 42) (Table 2). Patients in the efavirenz group had 
significantly more drug-related adverse events as well. This 
disparity was mostly accounted for by the well-documented 
central nervous system side effect profile of efavirenz.31 In 
light of the above results, raltegravir was approved by the 
FDA to treat antiretroviral-naïve   HIV-1-infected patients on 
July 9, 2009.HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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Table 2 Summary of major clinical studies of raltegravir
Study Phase No. of participants Study regimen VL , 50 CD4 countΔ Comment/ref #
Protocol 004
Part 1 II 35 treatment-naïve,  
HIV-1-infected  
patients
RAL (100, 200,  
400, 600 mg), or  
placebo twice daily  
for 10 days
N/A N/A VL ↓1.9log10  
(RAL 100 mg) 2.0log10 
(RAL 200 mg) 1.7log10 
(RAL 400 mg) 2.2log10 
(RAL 600 mg)27
Part 2 II 198 treatment-naïve,  
HIV-1-infected  
patients
TDF + 3TC and  
RAL 100, 200, 400,  
or 600 mg twice daily  
or eFV for 48 weeks
85% (RAL 100 mg)  
83% (RAL 200 mg)  
88% (RAL 400 mg)  
88% (RAL 600 mg)  
87% (eFV)
↑221 (100 mg)  
↑146 (200 mg)  
↑144 (400 mg) 
↑187 (600 mg)  
↑170 (eFV)
28
extension II 198 treatment-naïve,  
HIV-1-infected  
patients
TDF + 3TC and  
RAL 400 mg twice  
daily or eFV for  
96 weeks
83% (RAL)  
84% (eFV)
↑221 (RAL)  
↑232 (eFV)
29
STARTMRK  
48 weeks
 
III
 
563-treatment-naïve,  
HIV-1-infected  
patients
 
TDF + FTC and  
RAL 400 mg twice  
daily of eFV
 
86% (RAL)  
82% (eFV)
 
↑189 (RAL)  
↑163 (eFV)
 
30
96 weeks III 477 treatment-naïve,  
HIV-1-infected patients
Same as above 81% (RAL)  
79% (eFV)
↑240 (RAL)  
↑225 (eFV)
31
Protocol 005  
24 weeks
 
II
 
178 treatment-  
experienced, HIV-1-  
infected patients
 
OBT plus RAL  
(200, 400, or 600 mg)  
twice daily or placebo
 
65% (RAL 200 mg)  
56% (RAL 400 mg)  
67% (RAL 600 mg)  
13% (placebo)
 
↑63 (200 mg)  
↑113 (400 mg)  
↑94 (600 mg)  
↑5.4 (placebo)
 
32
96 weeks same as above OBT plus RAL  
400 mg twice  
daily or placebo
55% (RAL) ↑104 (RAL) 33
BENCHMRK  
48 weeks
  Trial 1
 
III
 
350 treatment-  
experienced HIV-1-  
infected patients
 
OBT and RAL 400 mg  
twice daily or placebo
 
65% (RAL)  
31% (placebo)
 
↑109 (RAL)  
↑45 (placebo)  
(Trial 1 and 2)
 
34
  Trial 2 349 treatment-  
experienced HIV-1- 
infected patients
Same as above 60% (RAL)  
35% (placebo)
See above
96 weeks  
    (Trial 1  
and 2)
 
III
 
699 treatment-  
experienced HIV-1-  
infected patients
 
Same as above
 
57% (RAL)  
26% (placebo)
 
↑123 (RAL)  
↑49 (placebo)
 
35
SwTCHMRK III 702 HIV-1-infected  
patients with viral 
suppression on  
LPV/r-based regimen
OBT + LPV/r or  
switch to OBT + RAL  
for 24 weeks
84% (RAL)  
91% (control)
↑5–17  
(both groups)
58
SPIRAL III 273 HIV-1-infected  
patients with viral 
suppression on PI-  
based regimen
OBT + PI/r or  
switch to RAL for  
48 weeks
89% (RAL)  
87% (control)
↑46 (RAL)  
↑44 (placebo)
59
SHIeLD II 35 treatment-naïve  
HIV-1-infected  
patients
Single arm of  
ABC/3TC + RAL  
for 48 weeks
91% ↑247 First study looking  
at RAL with 
alternative NRTI 
background62
SPARTAN II 93 treatment-naïve  
HIV-1 infected-patients
ATV/RAL or ATV/r +  
TDF/FTC for 24 wks
75% (ATV/RAL)  
63% (ATV/r +  
TDF FTC)
Not reported Terminated early 
due to resistance 
in ATV/RAL group, 
hyperbilirubinemia22
Abbreviations: ATV, atazanavir; ABC, abacavir; 3TC, lamivudine; eFV, efavirenz; FTC, emtricitabine; LPV/r, lopinavir/ritonavir; OBT, optimized background therapy; PI, 
protease inhibitor; RAL, raltegravir; TDF, tenofovir; VL, viral load.HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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Treatment experienced patients
The Protocol 005 study was a phase II, double-blind clinical 
trial, which investigated the safety and efficacy of raltegravir 
in combination with optimized background regimens (OBT) in 
HIV-infected patients with multidrug-resistant virus. Patients 
enrolled in the study were required to be infected with HIV 
documented to be resistant to at least one NNRTI, one NRTI, 
and one protease inhibitor (PI). Patients also had to be on a 
stable antiretroviral regimen for at least 3 consecutive months 
before enrollment. The screening entry viral load threshold 
was 5000 copies/mL with a CD4 count of at least 50 cells/µL. 
A total of 179 patients were enrolled in the study including 
44 who received raltegravir 200 mg twice daily + OBT, 45 
assigned to 400 mg twice daily + OBT, and 45 who received 
600 mg twice daily + OBT. Another 45 patients were ran-
domized to receive placebo + optimized background therapy. 
The quality of the selected OBT was stratified by genotypic 
and phenotypic sensitivity, with a score of “1” representing 
one drug to which the virus was fully sensitive. From this a 
summative genotypic and phenotypic sensitivity score (GSS 
and PSS) was derived (Table 3). The primary endpoint was 
change in viral load from baseline at 24 weeks. At the primary 
endpoint (24 weeks), the mean decrease from baseline viral 
load in the raltegravir groups was -1.80log10 in the 200 mg 
group, -1.87log10 for the 400 mg group and -1.84log10 for the 
600 mg group. The baseline viral load decrease in the placebo 
group was 0.35log10. The proportion of patients who achieved 
a viral load , 50 copies at week 24 was 65% in the 200 mg 
raltegravir arm, 56% in the 400 mg arm, and 67% in the 
600 mg arm. Only 16% of those assigned to the placebo group 
reached this level of viral suppression at 24 weeks. Adverse 
event profiles were similar in all groups.32 Subsequently, Pro-
tocol 005 was extended to an open label phase for a follow-up 
period of 96 weeks. All patients from the double-blind phase 
were offered the opportunity to continue raltegravir at 400 mg 
twice daily. Eighty-six patients from the raltegravir group and 
6 patients from the placebo group completed 96 weeks of 
raltegravir 400 mg twice daily, 48% of whom achieved HIV 
RNA levels of ,50 copies/µL at 96 weeks. The mean increase 
in CD4 count in the group was 104 cells/µL at 96 weeks.33
Given the favorable results of the phase II trial, the 
BENCHMRK trials were initiated with the purpose of 
validating the antiretroviral efficacy of raltegravir as part of 
an optimized treatment regimen for HIV-infected patients 
with multi-drug resistant virus. BENCHMRK-1 and 2 were 
identical trials organized simultaneously in two different 
geographical regions. BENCHMRK-1 was conducted in 
Europe, Asia, Australia, and Peru, while BENCHMRK-2 
was organized mainly in North and South America. A total 
of 699 patients participated in these studies, 462 randomized 
to raltegravir 400 mg twice daily + OBT and 237 randomized 
to placebo + OBT. As in Protocol 005, all enrollees had to 
be infected with HIV-1 virus resistant to at least one PI, one 
NNRTI, and one NRTI. The primary endpoint was the pro-
portion of patients who achieved viral load of ,400 copies/
mL at weeks 16 and 48. At any point in the study after week 
16, patients in the placebo arm had the opportunity to enter an 
open-label phase to receive raltegravir as part of their ARV 
regimen. At week 16, 77.5% of patients in the raltegravir group 
and 41.9% of patients in the placebo group achieved viral loads 
of ,400 copies/uL; 61.8% of the raltegravir group and 34.7% 
of the placebo group reached a viral load of ,50 copies/mL. 
At 48 weeks, 62.1% of the raltegravir group maintained viral 
loads ,50 copies/mL compared with 32.9% of the placebo 
group (P , 0.001).34 Both studies were extended to 96 weeks. 
Of the raltegravir recipients, 57% achieved a viral load of ,50 
copies/mL at 96 weeks compared with 26% of remaining on 
placebo. The mean increase in the CD4 count was 123 cells/uL 
in the raltegravir group and 49 cells/uL in the placebo group. 
Interestingly, 41% of patients with a genotypic sensitivity 
score (GSS) of ‘0’ maintained viral loads ,50 copies/mL 
Table 3 Response to raltegravir based on Genotypic (GSS) and 
Phenotypic Sensitivity Score (PSS) in BeNCHMRK Trials
HIV RNA level , 50 copies/mL
Raltegravir group Placebo group
Genotypic sensitivity score
  48 weeks
  0 45% 3%
  1 67% 37%
  2 77% 62%
    3 or more 71% 52%
  96 weeks
  0 41% 5%
  1 72% 28%
  2 70% 61%
  $3 53% 38%
Phenotypic sensitivity score
  48 weeks
  0 51% 2%
  1 61% 29%
  2 71% 39%
  3 71% 61%
  96 weeks
  0 48% 5%
  1 65% 24%
  2 69% 35%
  3 54% 48%
Note: Genotypic (GSS) and Phenotypic Sensitivity score is a measure  of how many 
drugs are active against the subject’s virus. For example, a GSS of ‘1’ denotes that 
the patient has one drug determined to be active based on serum HIV-1 genotype 
assay against the subject’s virus.HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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at week 96,   suggesting that this subset of patients achieved viral 
  suppression essentially on   raltegravir monotherapy (Table 3). 
Although an interesting finding, raltegravir monotherapy is still 
not recommended in patients with multi-resistant virus as some 
of the other agents had partial antiretroviral   activity even in the 
presence of extensive in vitro resistance.35 Given the results of 
the BENCHMRK studies, raltegravir was granted accelerated 
approval for use in the treatment of patients with multiresistant 
HIV virus by the FDA on October 12, 2007.
Safety and tolerability
A trial of 35 HIV-infected patients who received   raltegravir 
for 10 days showed that the adverse effect profile of 
  raltegravir was similar to placebo. The only drug-related 
laboratory abnormality was an elevation in alanine 
  aminotransminase in one patient. This abnormality resolved 
without interruption in therapy.27 In the 96-week follow-up 
period of Protocol 004, 51% of patients taking raltegravir 
reported adverse events that were judged by the investigators 
to be drug-related. Most of these events were mild, including 
headaches, nausea, and diarrhea. In the raltegravir group, 10 
patients (6.3%) experienced significant elevations in creatine 
phosphokinase (CPK), greater than 10 times the upper limit 
of normal (ULN). This was only reported in 3% of patients 
in the efavirenz group. Only four of the 10 cases were judged 
to be drug-related and there were no reports of rhabdomy-
olysis. Raltegravir was stopped temporarily in one patient. 
Overall, 51% of the patients in the raltegravir group vs 74% 
of the patients in the efavirenz group had any drug-related 
adverse events. In contrast to the lipid elevations seen in the 
efavirenz arm, lipid profiles in the raltegravir group were 
virtually unchanged from baseline after 96 weeks.29
The Phase III STARTMRK study validated most of the 
findings in Protocol 004. 47% of patients in the raltegravir 
group experienced adverse events judged to be drug-related at 
96 weeks. This was significantly lower than in the   efavirenz 
group in which 78% of the patients reported a drug-related 
adverse event. There was one reported case of severe 
  myopathy in a patient receiving raltegravir during the study 
period. The patient recovered without discontinuation of 
raltegravir. The most common drug-related adverse event 
in the raltegravir groups was headache (3.9% of patients). 
As in Protocol 004, there were no significant changes in 
lipid profile from baseline in the raltegravir group after 96 
weeks. Changes in total cholesterol, low-density lipoprotein 
cholesterol, high-density lipoprotein cholesterol, and triglyc-
eride levels were smaller in the raltegravir group than in the 
efavirenz group (P , 0.001).34,36
In the Phase II Protocol 005 study of HIV-1 infected 
patients with multi-resistant virus, the adverse event   profile 
of the raltegravir + OBT group was similar to that of 
  placebo + OBT, a finding validated by the safety data from 
the larger Phase III BENCHMRK studies. Again, Grade 4 
CPK elevations (.20 × ULN), were more common in the 
raltegravir group than in the placebo group (3% vs 0.8% 
in placebo), but none of these cases were associated with 
rhabdomyolysis or clinically apparent myopathy.33
In the first 3 years after FDA approval, four cases of 
rhabdomyolysis suspected to be caused by raltegravir were 
reported in the literature. There was considerable variability 
in the duration of exposure to raltegravir before the onset 
of rhabdomyolysis in these cases, ranging from 10 days to 
23 months. Most importantly, all four of the reported patients 
had significant risk factors predisposing them to myopathies 
of any cause at the time of raltegravir initiation. The first 
patient had chronic renal insufficiency (SCr of 2.3) and was 
receiving concomitant intravitreal foscarnet injections for 
cytomegalovirus retinitis.37 The second patient was taking 
pravastatin and tenofovir at baseline.38 The other two patients 
were co-infected with hepatitis C virus, one of whom had 
documented elevations in creatine kinase on a previously 
received nonraltegravir-based regimen.39,40 Given these 
conditions, causation could not be definitively established 
in any of the cases. Nevertheless, raltegravir should be used 
with caution or not at all in individuals at increased risk 
of myopathies, as recommended by the FDA and the drug 
manufacturer.2
Resistance to raltegravir
As with other classes of antiretrovirals, integrase inhibi-
tors are subject to the dynamic adaptablility of the HIV-1 
viral genome.11,41 All the major mutations responsible for 
decreased susceptibility to raltegravir appear to localize 
around the active site of the IN enzyme.42 In vitro data 
  suggest that an accumulation of mutations in the IN enzyme 
is necessary before phenotypic resistance to raltegravir is 
conferred.43,44 Distinct subsets of mutations in the IN enzyme 
have been characterized in the viral sequences of patients 
who have failed raltegravir. The primary mutations have been 
identified as Q148H , N155H, and Y143R/C, with the major 
secondary mutations being E92Q and G140S. All these 
amino acid residues correspond to the active site of the IN 
enzyme.45–47 Genotypic sequencing studies in serum samples 
of 67 BENCHMRK patients who failed raltegravir revealed 
that the Q148H and N155H integrase mutations were mutu-
ally exclusive. Furthermore, the secondary mutation E92Q HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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invariably clustered with the N155H mutation while the 
G140S tended to be found in the Q148H mutants.36
Further investigations showed that the secondary inte-
grase mutations enabled a selection advantage (Table 4).48–51 
All the aforementioned mutations confer decreased pheno-
typic susceptibility to raltegravir alone; however, viruses with 
these mutations have substantial decreases in their replicative 
capacity in the absence of raltegravir compared with wild-
type virus. The secondary mutations appear to amplify the 
resistance of the virus to raltegravir while also restoring the 
replicative capacity of Q148H mutant virus essentially to 
wild-type virus levels.50,51
The prominence of these distinct mutations has been 
corroborated by clinical data. Genotypic sequencing was 
conducted on 94 of 105 raltegravir recipients who failed 
raltegravir by week 48 in the BENCHMRK trials; 67% of 
these patients had mutations at either amino acid 148, 155, 
or 143. Among this subset of patients, 30% had the Q148H 
mutation and 43% had a mutation at residue 155.36 As 
previously noted, the N155H single mutant has a slightly 
enhanced viral fitness in the absence of raltegravir than 
Q148H. However, addition of G140S to Q148H gives it a 
substantial fitness advantage over N155H. More importantly, 
the G140S mutation gives the Q148H mutant an IC50 that is 
five times greater than the E92Q/N155H double mutant, 20 
times greater than the Q148H single mutant, and 245 times 
greater than wild-type.50 Longitudinal clonal analysis of 
virus isolated from HIV-1 patients who failed raltegravir has 
shown that in early virologic failure, the N155H mutant is   
prominent.52 However, selection pressure of subsequent expo-
sure to raltegravir favors the predominance of the Q148H/
G140S mutant over time.53,54 Q148H, N155H, or Y143C 
were almost never identified in the integrase sequence of 
  raltegravir-naïve patients.55,56 The above mutations have also 
been shown to confer some degree of resistance to all the cur-
rent integrase inhibitors in development, including elvitegra-
vir, and second generation integrase inhibitors MK-2048 and 
GSK-572. These mutations have not been shown to affect the 
efficacy of antiretrovirals of any other class to date.57
Current considerations  
in the clinical use of raltegravir
Given the substantial clinical evidence that raltegravir has 
minimal effect on lipid profiles compared with other classes 
of antiretrovirals, a series of studies was conducted to investi-
gate whether switching from a PI-based to a raltegravir-based 
regimen maintained viral suppression. The largest studies 
were the SWITCHMRK trials. The goal of these trials was to 
determine whether patients who achieved viral suppression 
on lopinavir/ritonavir (LPV/r) could maintain viral suppres-
sion at acceptable levels after switching to raltegravir while 
at the same time achieving improvements in lipid profiles 
(the primary endpoint of the SWITCHMRK study). Seven 
hundred and two patients were evenly randomized to receive 
  raltegravir or maintain their current lopinavir/r based regi-
men. All   participants were required to have achieved viral 
suppression on a LPV/r based regimen for at least 3 months 
prior to   randomization. In the combined trials (SWITCH-
MRK 1 and 2), 84.4% of the patients who switched to ralte-
gravir maintained viral loads , 50 copies/mL at 24 weeks, 
compared with 90.6% of patients who stayed on LPV/r. The 
lower limits of the 95% confidence interval for the differ-
ence between the raltegravir group and the LPV/r group in 
SWITCHMRK 1 and 2 studies were -14.4% and -12.2%, 
respectively. Both these values exceeded the predetermined 
study threshold of noninferiority which was -12%, thus 
establishing inferiority of the switch strategy.58 The SPIRAL 
study, conducted primarily in Spain, looked into the same 
question: 273 patients were randomized either to remain on 
their protease inhibitor-based regimen or switch to raltegra-
vir. In contrast to the SWITCHMRK study population, the 
median time of viral suppression before randomization in 
the SPIRAL study was 73 months. In this study, 89% of the 
raltegravir group and 87% of the PI group maintained viral 
suppression , 50 copies/mL after 48 weeks, confirming the 
noninferiority of raltegravir in this study. The authors of the 
SPIRAL study speculate that longer periods of viral sup-
pression in their cohort at the time of study enrollment may 
be the primary reason why their raltegravir group had better 
outcomes than in SWITCHMRK. In SWITCHMRK, the 
average duration of time on antiretroviral therapy for patients 
Table  4  effect  of  HIV  integrase  mutations  on  raltegravir 
sensitivity48–51
HIV integrase mutation Fold change from WT RAL IC50
N155H 16
Q148H 18
Q148R 34
Y143R ∼30
N155H + e92Q .150
Q148H + G140S 521
Q148H + e138K 20
Q148H + G140A .150
Q148R + G140S 405
Q148R + e138K .150
Q148R + G140A .150
Abbreviations: IC50, concentration of raltegravir at which 50% of integrase strand 
transfer activity is inhibited in vitro; RAL, raltegravir; wT, wild-type.HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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who switched to raltegravir was 3.4 years.58,59 Clinical data 
assessing the potential for successful switch of virologically 
suppressed patients from enfurvitide to raltegravir have been 
more definitively shown to be safe and effective.60,61
The success of raltegravir in these various situations has 
prompted other studies looking at other less commonly used 
strategies. Raltegravir has recently shown efficacy when 
administered with alternate NRTI backgrounds. Data from 
the SHIELD study (RAL+ lamivudine/abacavir) showed 
that 31 of 35 HIV-1 treatment-naïve patients achieved viral 
suppression of ,50 copies/mL at 48 weeks.62 Recent studies 
investigating the efficacy of raltegravir-based NRTI sparing 
regimens have produced varying results. The SPARTAN 
study randomized treatment-naïve HIV-infected subjects to 
receive either unboosted atazanavir and raltegravir or rito-
navir boosted atazanavir + emtricitabine/tenofovir, one of 
the four “preferred” regimens in the 2011 DHHS guidelines. 
The trial was terminated prematurely due to higher rates of 
antiretroviral resistance among those with virologic failure 
and unacceptably high levels of hyperbilirubinemia in the ata-
zanavir/raltegravir group.22 The ongoing PROGRESS study 
is a 96-week trial comparing the combination of LPV/r and 
raltegravir to a regimen of LPV/r and tenofovir plus emtricit-
abine in treatment-naïve patients. According to 48-week data 
from this trial, 83% of patients in the RAL arm achieved the 
primary endpoint of HIV RNA , 40 copies/ml vs 85% in 
the TDF/FTC group, thus suggesting noninferiority.63 ACTG 
A5262 was a single-arm clinical trial that looked into the use 
of a novel combination of raltegravir and ritonavir-boosted 
darunavir in treatment-naïve patients. Surprisingly, in the 
48 week intention-to-treat analysis, only 62% of the 112 
patients achieved viral load of ,50 copies/mL (28 virologic 
failures, 15 discontinued trial prematurely). Although this 
was a single-arm study, the proportion of noncompleters 
during the study period raises concern.64 Investigations in 
a humanized mouse model have shown successful pro-
phylaxis from HIV-1 when the animals were administered 
species-equivalent doses of raltegravir. However, this was a 
proof-of-concept study and its clinical applicability is likely 
far in the future.65 Recent attempts at using raltegravir dose 
intensification to eradicate latent HIV reservoirs have proven 
to be unsuccessful.66–68 Raltegravir has been shown to have 
activity against xenotropic murine leukemia-related retrovi-
rus, a virus that may be associated with prostate cancer and 
chronic fatigue syndrome.69
A significant disadvantage to the clinical use of raltegravir 
is the requirement for twice-daily dosing to achieve maximal 
efficacy.2 Recent studies have shown that raltegravir is less 
efficacious in achieving and maintaining viral suppression 
when dosed once daily.70 The most important such study 
was the QDMRK study which demonstrated the drug’s loss 
of antiviral activity with once daily dosing. In this study, 
770 treatment-naïve patients were randomized to receive 
either raltegravir 400 mg twice daily or raltegravir 800 mg 
once daily. Both groups received tenofovir/emtricitabine as 
NRTI backbone. At 48 weeks, 88.9% of twice daily group 
achieved viral load , 50 copies/mL compared with 83.2% of 
the patients in the once daily group. The treatment difference 
was -5.7% (95% CI, -10.7% to -0.8%), thus establishing 
inferiority of once daily dosing over the approved twice daily 
regimen. In patients with a baseline viral load of .100,000 
copies/mL, 84.2% of patients achieved viral load , 50 
  copies/mL with twice daily dosing compared with 74.3% in 
the once daily group. There was no statistically significant 
difference between the dosage groups in patients with base-
line viral load of , 100,000 copies/uL.71
Elvitegravir (GS-9137), is a potent inhibitor of HIV-1 inte-
grase activity developed by Gilead Sciences. When boosted 
by ritonavir, elvitegravir’s systemic exposure is increased 
by 20-fold, thus allowing persistent plasma levels suitable 
for once daily dosing.61 Phase II clinical trials showed that 
elvitegravir achieved viral suppression rates comparable to 
that of a ritonavir-boosted protease inhibitor at 24 weeks. 
Phase III studies on this drug are ongoing.72 Interestingly, 
elvitegravir appears to exhibit decreased activity against 
when the integrase gene has the Q148H/G140S as well as 
the N155H/E92Q mutations.53,57 The investigational integrase 
inhibitor dolutegravir (formerly known as S/GSK1349572, 
Shionogi/Glaxo Smith Kline) has been shown in phase I/II 
trials to have excellent activity in antiretroviral-naïve HIV-
infected patients. It also appears to have significant antiviral 
activity against HIV viruses with some patterns of resistance 
after viral failure of raltegravir. Early data from the VIKING 
trial show potent antiviral activity in many patients who 
had previously failed raltegravir. The primary short-term 
endpoint was the proportion of patients who achieved a viral 
load , 400 copies/mL or 0.7log10 change of viral load below 
their baseline value after 10 days of therapy. In VIKING I, 
patients were given dolutegravir 50 mg once daily + OBT; 
78% of these patients achieved the primary endpoint on 
Day 11. Interestingly, all of the six patients who failed to 
reach the endpoint harbored the Q148H mutation. When 
dolutegravir was given at 50 mg twice daily in VIKING II, 
96% of these patients achieved the primary endpoint, includ-
ing all of the patients with Q148H.73,74 Data at 24-weeks for 
the VIKING trials are pending. Nevertheless, potent   antiviral HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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activity against raltegravir-resistant virus as well as its long 
half-life without the need for pharmacologic boosting makes 
it a promising prospect as part of a new generation of inte-
grase inhibitors.75
Role in therapy
Extensive clinical data have shown the efficacy of raltegravir 
in the management of HIV-infection in both treatment-naïve 
and treatment-experienced patients. Accordingly, raltegravir 
plus emtricitabine/tenofovir has been named as one of the 
“preferred” regimens for initial therapy of HIV-infected 
patients, in the United States Department of Health and Human 
Services (DHHS) guidelines as updated in January 2011.76 As 
stated above, ongoing studies are being conducted to confirm 
its safety and efficacy with other NRTI combinations.61 It’s 
favorable side effect profile in comparison to all other anti-
retrovirals as well as its minimal impact in lipid homeostasis 
has made it a strong option for the treatment of an array 
of HIV-1 infected patients. Raltegravir’s efficacy in highly 
treatment-experienced patients highlight the drug’s versatility. 
Given the availability of other potent and safe antiretroviral 
regimens for treatment-naïve patients, some clinicians prefer 
to reserve raltegravir for patients with multiply drug-resistant 
HIV infection. Others believe the advantages of raltegravir 
should be exploited early in the treatment sequence. Reports 
of the long-term success of etravirine, raltegravir, and boosted 
darunavir salvage regimens in patients with highly resistant 
HIV are intriguing.77 Enthusiasm for more widespread use of 
raltegravir is tempered by cost considerations in some settings. 
Nevertheless, raltegravir’s generally favorable safety profile 
and its superior potency in suppression of HIV-1 replication 
will likely ensure its place in the range of successful HIV-1 
antiretroviral treatment options for years to come.
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